These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27334506)

  • 1. A quality improvement initiative to increase pneumococcal vaccination coverage among children after kidney transplant.
    Malone K; Clark S; Palmer JA; Lopez S; Pradhan M; Furth S; Kim J; Fisher B; Laskin B
    Pediatr Transplant; 2016 Sep; 20(6):783-9. PubMed ID: 27334506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of near-real-time medical claims data to generate timely vaccine coverage estimates in the US: the dynamics of PCV13 vaccine uptake.
    Schuck-Paim C; Taylor R; Lindley D; Klugman KP; Simonsen L
    Vaccine; 2013 Dec; 31(50):5983-8. PubMed ID: 24144470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of various types of patients' reminders on the uptake of pneumococcal vaccine in adults: A randomized controlled trial.
    Ghadieh AS; Hamadeh GN; Mahmassani DM; Lakkis NA
    Vaccine; 2015 Oct; 33(43):5868-5872. PubMed ID: 26232345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving Pneumococcal Vaccination Rates in Rheumatology Patients by Using Best Practice Alerts in the Electronic Health Records.
    Sheth HS; Grimes VD; Rudge D; Ayers B; Moreland LW; Fischer GS; Aggarwal R
    J Rheumatol; 2021 Sep; 48(9):1472-1479. PubMed ID: 33323531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving influenza and pneumococcal vaccination uptake among incident peritoneal dialysis patients: a quality improvement initiative.
    Tan HZ; Phang CC; Wu SY; Sim MH; Law MM; Foo MWY; Htay H
    Int Urol Nephrol; 2021 Oct; 53(10):2167-2175. PubMed ID: 33675479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An initiative to improve pneumococcal immunization counseling in children with nephrotic syndrome.
    Sandokji I; Anderson LS; Warejko JK; Emerson BL; Greenberg JH
    Pediatr Nephrol; 2022 Jun; 37(6):1333-1338. PubMed ID: 34734331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving Pneumococcal Vaccination Rates in Cochlear Implant Programs: A Systematic Review and Meta-analysis.
    Britt AF; Poupore NS; Nguyen SA; White DR
    Otolaryngol Head Neck Surg; 2023 Mar; 168(3):291-299. PubMed ID: 35852861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged ≤59 months---selected U.S. regions, 2010--2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Nov; 60(43):1477-81. PubMed ID: 22048728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using an Inpatient Quality Improvement Curriculum for Internal Medicine Residents to Improve Pneumococcal Conjugate Vaccine Administration Rates.
    Jolin J; van Aalst R; Volpp B; Taylor T; Cohen E
    Jt Comm J Qual Patient Saf; 2018 Jun; 44(6):328-333. PubMed ID: 29793882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥2 years: an open-label study.
    Cordonnier C; Ljungman P; Juergens C; Maertens J; Selleslag D; Sundaraiyer V; Giardina PC; Clarke K; Gruber WC; Scott DA; Schmoele-Thoma B;
    Clin Infect Dis; 2015 Aug; 61(3):313-23. PubMed ID: 25870329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse Reactions to Pneumococcal Vaccine in Pediatric and Adolescent Patients with Sickle Cell Disease.
    Han J; Kemiki O; Hsu LL; Rivers AE
    Pharmacotherapy; 2015 Jul; 35(7):696-700. PubMed ID: 26095207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of a guideline-based best practice alert on pneumococcal vaccination rates in adults in a primary care setting.
    McAdam-Marx C; Tak C; Petigara T; Jones NW; Yoo M; Briley MS; Gunning K; Gren L
    BMC Health Serv Res; 2019 Jul; 19(1):474. PubMed ID: 31291959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementing a Multidisciplinary Approach to Enhance Compliance With Guideline-Recommended Prechemotherapy Pneumococcal Vaccination in a Military-Based Medical Oncology Practice.
    Delacruz W; Terrazzino S; Osswald M; Payne C; Haney B
    J Oncol Pract; 2017 Nov; 13(11):e966-e971. PubMed ID: 28876159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.
    Greenberg RN; Gurtman A; Frenck RW; Strout C; Jansen KU; Trammel J; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2014 Apr; 32(20):2364-74. PubMed ID: 24606865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of an Electronic Health Record (EHR) Reminder on Human Papillomavirus (HPV) Vaccine Initiation and Timely Completion.
    Ruffin MT; Plegue MA; Rockwell PG; Young AP; Patel DA; Yeazel MW
    J Am Board Fam Med; 2015; 28(3):324-33. PubMed ID: 25957365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Kobayashi M; Bennett NM; Gierke R; Almendares O; Moore MR; Whitney CG; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2015 Sep; 64(34):944-7. PubMed ID: 26334788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
    Cho BH; Stoecker C; Link-Gelles R; Moore MR
    Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.